Human Papillomavirus Infection Clinical Trials

Find Human Papillomavirus Infection Clinical Trials Near You

Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged \ 14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to a multi-year cohort of boys (intervention arm). The CRT will be conducted in 26 communities/clusters (13 per arm) in northern Tanzania. Boys aged 14 to 18 years in the intervention arm will receive one dose of the 4-valent HPV vaccine (Gardasil®) that protects against HPV 6, 11, 16, and 18. Population genital HPV prevalence in 18 to 21-year-olds will be compared between intervention clusters (female and male vaccination) and control clusters (female vaccination only) at 3 years after the intervention. Blood sampling for immune responses and adverse event data collection will be performed in a subset of 200 male subjects in selected intervention clusters.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 14
Maximum Age: 18
Healthy Volunteers: t
View:

• Parents and adult male participants (aged 18 years) must sign an ICF and male participants aged less than 18 years must sign an informed assent form (IAF), indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and to receive HPV vaccination. If the parent or participant cannot read or write, the procedures must be explained and informed consent/assent must be witnessed by a literate third party who is not involved in the conduct of the study.

• Participants must have been born male, and must be aged 14 to 18 years inclusive at time of vaccination.

• Participants must be living in an intervention community (cluster).

• Participants must be willing and able to comply with the protocol requirements.

• Participants must agree to avoid all non-trial immunisations in the 14 days following vaccination with the trial vaccine, other than emergency vaccinations such as post-exposure rabies or tetanus vaccinations.

• Participants must be healthy as determined by a medical history. A physical examination will be conducted if necessary according to the clinician's judgement.

Locations
Other Locations
United Republic of Tanzania
Mwanza Intervention Trials Unit
RECRUITING
Mwanza
Contact Information
Primary
Deborah Watson-Jones, MD, PhD
deborah.watson-jones@lshtm.ac.uk
Time Frame
Start Date: 2022-08-01
Estimated Completion Date: 2026-12
Participants
Target number of participants: 10400
Treatments
Experimental: Male vaccination + national HPV vaccination programme
Single dose of the 4-valent HPV vaccine (Gardasil®; Merck \& Co.) offered to all eligible boys aged 14 to 18 years in the 13 intervention communities. Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
Active_comparator: National HPV vaccination programme only
Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
Related Therapeutic Areas
Sponsors
Collaborators: University of Cambridge, Cancer Epidemiology Research Programme Institut Català d' Oncologia, York Biomedical Research Institute, Hull York Medical School, University of York, Mwanza Intervention Trials Unit, National Institute for Medical Research, Karolinska Institute Department of Laboratory Medicine
Leads: London School of Hygiene and Tropical Medicine

This content was sourced from clinicaltrials.gov